Conexeu
Conexeu Sciences is a biotechnology company developing a patented collagen-based extracellular matrix (ECM) scaffold platform for tissue regeneration, with applications in wound care, aesthetics, oral health, animal health, and 3D bioprinting.
- CEO / Founder
- Miles Harrison
- Team Size
- 1-10
- Stage
- Early Stage
- Total Funding
- $5.0M
- Latest Round
- Crowdfunding
Technology & Products
Key Products
CXU (collagen-based ECM scaffold platform — injectable regenerative device and printable bioink); Ten Minute Tissue (collagen-based ECM wound care product, pre-510(k) submission targeted for Q3 2026); 3D bioprinted collagen-based ECM scaffolds for personalized tissue reconstruction
Technological Advantage
Patented CXU platform is both an injectable medical device and a 3D-printable ECM bioink — a single united platform for today's clinic and tomorrow's biofabrication. Thermosensitive self-crosslinking at body temperature. Demonstrated ability to 3D-print functional collagen-based ECM scaffolds that promote neovascularization. Regulatory pathway: Ten Minute Tissue pre-510(k) submission targeted Q3 2026.
Differentiation
Value Proposition
Proprietary collagen-based ECM platform (CXU) that is thermosensitive (liquid at room temperature, self-crosslinks to gel at ~37C), biomimetic, and supports neovascularization, cell migration, and organized tissue regeneration — moving beyond static fillers toward true tissue restoration
How They Differentiate
Unlike synthetic polymer scaffolds or non-functional collagens, CXU is a medical-grade, collagen-based ECM that is biomimetic, thermosensitive, and supports vasculogenesis — the body recognizes and integrates it as native tissue. Single platform spans injectables (wound care, aesthetics) and 3D bioprinting (personalized implants).
Market & Competition
Target Customers
Plastic surgeons, dermatologists, wound care specialists, dental surgeons, veterinary surgeons, and medical device companies in aesthetics, wound care, oral health, and reconstructive surgery
Industry Verticals
Medical aesthetics; Wound care; Oral/dental health; Reconstructive surgery; Veterinary medicine; 3D bioprinting/tissue engineering
Competitors
CollPlant (collagen-based bioinks for 3D bioprinting); Galderma/Merz Aesthetics (dermal fillers — traditional non-regenerative approach); Organovo (3D bioprinted tissue models)
Growth & Milestones
Major Milestones
Founded Nov 2022; Raised $5M maximum Reg CF via Equifund (Oct 2025); Appointed Miles Harrison as President & CEO (2025); First-ever 3D-printed functional collagen-based ECM scaffolds (Nov 2025); Filed S-1/A for Nasdaq listing under symbol CNXU (2026); Recognized as Top Regenerative Medicine Solution Provider 2026 by Life Sciences Review Magazine